Reg charity nos. 1139257/SCO41990. Registered as a limited company in England and Wales no. 07451571
0808 800 8000 Free call
LOW DOSE NALTREXONE
Otherwise known as LDN
On Saturday the 10th September David Taylor attended the MS Society’s AGM and put forward a resolution on LDN which was passed with 3,729 votes for and 73 against.
Head Office promised to review the evidence of LDN by the end of December 2011. They have now reported back directly to the proposer Heather Fairweather. The information is on their web site and the link is now available via a link from this page:
In a nutshell The MS Society have stated there is currently not enough evidence-based information to prove LDN is an effective treatment for MS. The MS Society supports an evidence-based approach to research and as such does not recommend that people take unproven treatments outside of a properly regulated clinical trial.
It is a fact, however, that many doctors offer licensed drugs, but not necessarily licensed for MS to their MS patients
Until LDN is licenced it will not be readily available for anyone wishing to try it.
We are therefore back to where we started but hopefully the press and media coverage given to this issue will have alerted many who were unaware of the possible relief this medication may give.
It would seem medical opinion would appear to have more weight than anecdotal evidence although the majority of the anecdotal evidence has been given by doctors at various conferences.
This reply from Head Office does not come as a surprise and therefore if you go to the link above you will see that Head Office do not advise LDN as an option for MS patients.
In December there was a debate on LDN in the Houses of Parliament and you can view this on
http://www.theyworkforyou.com/debates/?id=2011-12-08a.490.0
Should anyone wish to try this treatment of their own free will they should look up all the information available on many of the LDN web sites and contact their G.P.